We are live on ! Find out more
SCM

Stonepine Capital Management Portfolio holdings

AUM $177M
1-Year Est. Return 91.13%
This Fund
S&P 500
This Quarter Est. Return
-3.86%
1 Year Est. Return
+91.13%
3 Year Est. Return
+230.7%
5 Year Est. Return
+260.67%
10 Year Est. Return
+2,169.5%
AUM
$103M
AUM Growth
-$21.1M
Cap. Flow
-$8.51M
Cap. Flow %
-8.28%
Top 10 Hldgs %
58.07%
Holding
75
New
23
Increased
18
Reduced
24
Closed
9

Top Buys

Rank Stock Value
1
SRZN icon
Surrozen
SRZN
+$1.73M
2
ANIP icon
ANI Pharmaceuticals
ANIP
+$1.65M
3
ENTA icon
Enanta Pharmaceuticals
ENTA
+$1.6M
4
EDSA icon
Edesa Biotech
EDSA
+$1.48M
5
OPTN
OptiNose
OPTN
+$1.26M

Top Sells

Rank Stock Value
1
ADMA icon
ADMA Biologics
ADMA
+$7.45M
2
IRWD icon
Ironwood Pharmaceuticals
IRWD
+$2.87M
3
LKFT
Lakefront Biotherapeutics American Depositary Shares
LKFT
+$2.68M
4
ACAD icon
Acadia Pharmaceuticals
ACAD
+$2.3M
5
EOLS icon
Evolus
EOLS
+$1.7M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ANIP icon
1
ANI Pharmaceuticals
ANIP
$1.65B
$13.6M 13.28%
48,000
+27,600
+135% +$1.65M
EOLS icon
2
Evolus
EOLS
$598M
$13.6M 13.28%
1,134,574
-130,077
-10% -$1.7M
OPTN
3
DELISTED
OptiNose
OPTN
$7.23M 7.04%
788,647
+199,990
+34% +$1.26M
ZVRA icon
4
Zevra Therapeutics
ZVRA
$745M
$4.87M 4.74%
650,000
+52,300
+9% +$416K
VSTM icon
5
Verastem
VSTM
$723M
$3.7M 3.6%
613,000
-257,000
-30% -$1.57M
URGN icon
6
UroGen Pharma
URGN
$2.19B
$3.69M 3.59%
333,400
+9,076
+3% +$96.8K
SRZN icon
7
Surrozen
SRZN
$265M
$3.33M 3.24%
285,782
+148,582
+108% +$1.73M
ANIK icon
8
Anika Therapeutics
ANIK
$281M
$3.26M 3.17%
206,639
-31,583
-13% -$525K
ENTA icon
9
Enanta Pharmaceuticals
ENTA
$408M
$3.26M 3.17%
590,742
+258,842
+78% +$1.6M
AQST icon
10
Aquestive Therapeutics
AQST
$671M
$3.04M 2.96%
200,000
+40,000
+25% +$121K
ESTA icon
11
Establishment Labs
ESTA
$2.15B
$3.04M 2.96%
74,500
-5,502
-7% -$205K
INDV icon
12
Indivior Pharmaceuticals
INDV
$4.11B
$2.9M 2.82%
304,000
-1,000
-0.3% -$10.5K
ACRS icon
13
Aclaris Therapeutics
ACRS
$876M
$2.77M 2.69%
527,842
-135,563
-20% -$289K
DAWN
14
DELISTED
Day One Biopharmaceuticals
DAWN
$2.77M 2.69%
348,820
+113,820
+48% +$1.23M
XOMA
15
DELISTED
Xoma
XOMA
$2.59M 2.52%
129,813
+4,113
+3% +$99K
TELA icon
16
TELA Bio
TELA
$35.1M
$2.51M 2.44%
2,055,225
-297,874
-13% -$732K
LKFT
17
Lakefront Biotherapeutics American Depositary Shares
LKFT
$1.9B
$2.36M 2.3%
93,968
-106,032
-53% -$2.68M
IKT icon
18
Inhibikase Therapeutics
IKT
$352M
$2M 1.95%
914,973
-217,415
-19% -$546K
HRTX icon
19
Heron Therapeutics
HRTX
$62.7M
$1.75M 1.7%
796,100
+96,100
+14% +$187K
EDSA icon
20
Edesa Biotech
EDSA
$45.9M
$1.68M 1.63%
+687,500
New +$1.48M
MYO icon
21
Myomo
MYO
$55.5M
$1.33M 1.3%
276,707
+2,281
+0.8% +$13K
KROS icon
22
Keros Therapeutics
KROS
$220M
$1.02M 0.99%
+100,000
New +$1.16M
VIR icon
23
Vir Biotechnology
VIR
$1.94B
$937K 0.91%
144,628
-19,478
-12% -$173K
SCPH
24
DELISTED
scPharmaceuticals
SCPH
$914K 0.89%
347,687
-335,843
-49% -$1.09M
INO icon
25
Inovio Pharmaceuticals
INO
$141M
$845K 0.82%
518,331
-531,669
-51% -$1.07M
1
2 3

Similar funds

RP
Regeneron Pharmaceuticals Tarrytown, New York $177M AUM 9.82% 1-Year Est. Return
MSA
Marathon Strategic Advisors Pittsburgh, Pennsylvania $177M AUM 66.85% 1-Year Est. Return
HF
Holcombe Financial Atlanta, Georgia $177M AUM 13.35% 1-Year Est. Return
BFAG
Blackston Financial Advisory Group The Villages, Florida $177M AUM 21.44% 1-Year Est. Return
CWP
Clark Wealth Partners O'fallon, Illinois $177M AUM 22.36% 1-Year Est. Return
MVM
Medicxi Ventures Management St. Helier, Jersey $177M AUM 212.06% 1-Year Est. Return
CMP
Christine Messmer PC Collegeville, Pennsylvania $177M AUM
JESC
J.E. Simmons & Co Dallas, Texas $177M AUM

Stonepine Capital Management's Q1 2025 Portfolio in Review

As of Q1 2025, Stonepine Capital Management held 75 positions worth $103M, down 17% from $124M the previous quarter. Its ten largest holdings account for 58% of the portfolio.

Stonepine Capital Management withdrew a net $8.51M in Q1 2025, closing 9 positions and reducing 24 holdings. Its most notable exit was Ironwood Pharmaceuticals, an estimated $2.87M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 100% a quarter earlier.

Against the trend, Stonepine Capital Management opened a new position in Edesa Biotech worth $1.68M.

  • Stonepine Capital Management's largest Q1 2025 buy was Edesa Biotech: 687,500 shares worth $1.68M.
  • Stonepine Capital Management added most to Surrozen in Q1 2025, an estimated $1.73M increase.
  • Stonepine Capital Management's biggest Q1 2025 reduction was ADMA Biologics, cutting an estimated $7.45M.
  • Stonepine Capital Management fully exited Ironwood Pharmaceuticals in Q1 2025, selling an estimated $2.87M.
  • Stonepine Capital Management's ten largest holdings make up 58% of its $103M portfolio in Q1 2025.
  • Stonepine Capital Management opened 23 new positions and closed 9 in Q1 2025.
  • Stonepine Capital Management's portfolio value fell 17% quarter-over-quarter to $103M.

Based on Stonepine Capital Management's 13F filing for Q1 2025, filed 14 May 2025.